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Introduction
Allergic rhino-conjunctivitis affects more than 20% of the popu-
lation in western Europe,1 and represents a significant cause of 
illness with impact on daily activities and sleep quality.2 While 
many patients respond effectively to symptomatic pharmacother-
apy such as antihistamines and corticosteroids, a substantial pro-
portion of patients report inadequate symptom alleviation and 
reduced quality of life (QoL).3 Here, allergen-specific immuno-
therapy (SIT) offers a disease-specific causative treatment alter-
native by inducing tolerance to the allergen.4 Hence, patients who 
suffer from allergies in which allergen avoidance is not possible, 
such as pollen or house dust mite allergy, patients with systemic 
reactions to hymenoptera venom and patients whose symptoms 
have not responded adequately to optimal pharmacotherapy are 
usually the prime candidates for SIT.5
Until recently, SIT was predominantly administered subcu-
taneously (SCIT) as described in the early works by Noon and 
Freeman.6,7 SCIT comprises repeated administration of aller-
gen extracts, of as many as 50–80 injections over a period of at 
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Ige-mediated allergy is a highly prevalent disease in the 
industrialised world. allergen-specific immunotherapy (SIT) 
should be the preferred treatment, as it has long lasting 
protective effects and can stop the progression of the disease. 
However, few allergic patients choose to undergo SIT, due to 
the long treatment time and potential allergic adverse events. 
Since the beneficial effects of SIT are mediated by antigen 
presenting cells inducing Th1, Treg and antibody responses, 
whereas the adverse events are caused by mast cells and 
basophils, the therapeutic window of SIT may be widened by 
targeting tissues rich in antigen presenting cells. Lymph nodes 
and the epidermis contain high densities of dendritic cells and 
low numbers of mast cells and basophils. The epidermis has 
the added benefit of not being vascularized thereby reducing 
the chances of anaphylactic shock due to leakage of allergen. 
Hence, both these tissues represent highly promising routes 
for SIT and are the focus of discussion in this review.
New routes for allergen immunotherapy
pål Johansen,1 Seraina von Moos,2,† Deepa Mohanan,1 Thomas M. Kündig1 and Gabriela Senti2,*
1Department of Dermatology; university Hospital Zurich; Zurich, Switzerland; 2clinical Trials center; university Hospital Zurich; Zurich, Switzerland
†current affiliation: Division of Internal Medicine; university Hospital Zurich; Zurich, Switzerland
Keywords: allergy, immunotherapy, administration route, intralymphatic, epicutaneous, transcutaneous, clinical trials
Abbreviations: SIT, allergen specific immunotherapy; ILIT, intralymphatic immunotherapy; EPIT, epicutaneous immunotherapy; 
SLIT, sublingual immunotherapy; QoL, quality of life; DC, dendritic cells; LCs, Langerhans cells; APCs, Antigen presenting cells
least three years, but for immunotherapy to be effective, careful 
patient selection is required.8,9 Provided adequate precautions are 
taken, SIT is safe,10 but a decision whether to treat with immu-
notherapy will depend on a variety of factors, and conventional 
SCIT has a low appeal for most patients. Only approximately 5% 
of patients with allergic rhino-conjunctivitis choose to undergo 
immunotherapy, due to the long treatment duration with severe 
impact on daily life, e.g., numerous doctor visits with consequen-
tial absence from school or work. Personal and organizational 
factors then also determine whether one type of immunotherapy 
is more suitable than another, e.g., SCIT or the more patient-
friendly, but equally long and less validated sublingual immuno-
therapy (SLIT), which can be self-administered. In response to 
the drawbacks of SCIT and SLIT, current SIT research in allergy 
focuses on developing methods that are more patient-friendly in 
order to facilitate better patient compliance.4,5,11-13
One of the major challenges in this field of research is to balance 
efficacy and safety of the new SIT methods. Immunologically, 
SIT and conventional vaccination do not substantially differ.14 In 
conventional childhood vaccination, three injections of antigen 
and adjuvant are typically sufficient to induce long-term protec-
tion against vaccine-preventable diseases caused by microbes and 
higher doses typically produce stronger immune responses. From 
a qualitative viewpoint, it would be beneficial to use vaccines that 
are able to shift the type of immune response from allergy-associ-
ated T-helper type 2 (Th2) toward the more protective Th1 and 
Treg- based immune responses. This could be achieved by using 
higher doses of allergen with stronger Th1-stimulating adjuvants. 
However, in conventional SIT, high doses of antigen cannot be 
used since patients are allergic to the antigen used. Therefore, 
antigen doses in conventional SIT must be kept low to reduce the 
risk of patients suffering from local side effects and systemic and 
serious adverse effects. Hence, the goal of current SIT research is 
to allow strong stimulation of the immune system, while bypass-
ing potential adverse reactions.
Besides using hypo-allergenic and recombinant allergens, one 
strategy to improve the therapeutic window of SIT is to choose 
administration routes that allow efficient targeting of potent pro-
fessional antigen presenting cells (APCs), while avoiding tissues 
with high density of mast cells. Moreover, SIT in highly vascu-
larized tissues should also be avoided in order to avoid vascular 
leakage of allergen, which can cause systemic allergic reactions or 
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activation of dermal DC subsets has been found to be essential for 
B cell class switching and induction of a Th1-type response.24,25 In 
line with this, dermal DC subsets were observed to preferentially 
localize to the B-cell areas of draining lymph nodes, whereas LCs 
were observed to migrate to the T-cell areas.26 While previously 
considered mostly immunologically inactive and only forming 
part of the physical barrier function of the skin, keratinocytes 
have now been recognized to play a pivotal role in triggering and 
guiding the adaptive immune responses.23,27 These epithelial cells 
express different molecular mediators under different conditions, 
thereby governing dictating a variety of responses. A slight stress 
to the epithelium, such as abrasion, may trigger secretion of the 
IL-7-like cytokine thymic stromal lymphopoietin (TSLP), IL-25 
and IL-33, which in turn instruct non-inflammatory Treg- or 
Th2-type responses.28-32 On the other hand, epithelial damages 
may trigger expression of additional molecules such as IL-1α, 
IL-6 and TNF-α, which skew Th1-type responses.27 The degree 
of epithelial damage might explain the observed dichotomy of 
different DC subsets: while mild irritations induce non-inflam-
matory responses transmitted by LCs, stronger epithelial dam-
ages induce pro-inflammatory response performed by dermal 
DCs. The exact understanding of these processes would certainly 
support a more rational design of vaccines for epi- or transcutane-
ous administration.
Although the skin is easily accessible, topical application 
of a vaccine in a cream or in a patch does not typically induce 
an immune response because of the low permeability of vac-
cines through the stratum corneum. When, in ancient times, the 
Indians first used the skin to vaccinate against smallpox, the 
stratum corneum was disrupted by scratching, also called scari-
fication.33 Today, this has been replaced by tape stripping and 
other abrasive methods,34,35 which aim at gently removing the 
cornified keratinocytes without disrupting the underlying epider-
mal layers. Similarly, but more precisely, APCs of the epidermis 
can nowadays be directly targeted by using microneedle arrays 
with defined needle lengths thanks to latest technological prog-
ress.15,36-42 These methods are associated with physical irritation 
of keratinocytes, leading to secretion of cytokines, which in turn 
facilitates activation of the immune system.27,43 Alternatively, 
anaphylaxis. Two tissues which fit the above-described properties 
are the epidermal layer of the skin and the lymph nodes; the skin 
being the largest and most accessible organ system and the lymph 
nodes, the organs with the highest density of immune competent 
cells as well as being the final target of any vaccine antigen or SIT 
allergen. During the last decade, we and others have studied the 
use of these routes for vaccination and immunotherapy (Table 1) 
and in this review, we will discuss the outcomes of the research 
with a special focus on allergen-specific immunotherapy.
Epicutaneous Immunotherapy (EPIT)
The skin as an immunological organ in topical vaccination. 
Briefly, the human skin consists of the epidermis and the under-
lying dermis. Although the epidermis of the palms and soles are 
thicker by 1 mm, it typically forms a 50–150 µm thick mechani-
cal barrier with a 15–20 µm thick outer layer of cornified kera-
tinocytes in a lipid-rich matrix known as the stratum corneum, 
which effectively excludes the entry of large molecules.15-17 While 
predominantly consisting of keratinocytes, the epidermis also 
contains specialized cells such as pigment-producing melanocytes 
and antigen-presenting Langerhans cells (LCs).16 LCs account for 
only 3–5% of the epidermal cells, but are attractive targets for 
vaccines as they cover up to 20% of the skin surface by forming a 
network with their dendrites.15,18 The non-vascularized epidermis 
is separated by the basement membrane from the more complex 
dermis, which harbors a great diversity of cells as well as lym-
phatic and vascular conduits. Besides fibroblasts, macrophages 
and mast cells, the dermis comprises different subsets of dermal 
dendritic cells (DCs), as well as, depending on the inflammatory 
stage, other immune cells of myeloid or lymphoid origin.16,19
The skin with its associated lymphoid tissue (SALT) is con-
sidered an immunologically competent organ system.20 Although 
many of the immunologic properties of the skin are known,21 spe-
cific functions of the different DC subsets and the keratinocytes 
with regard to the stimulation and shaping of adaptive immune 
response remains to be unravelled.22,23 Whereas epidermal LCs 
have been demonstrated to hold a key role in elicitation of CD8+ 
T-cell responses and in shaping Th2-type/Treg-type responses, 
Table 1. clinical trials with allergen-specific intralymphatic (ILIT) or epicutaneous (epIT) immunotherapy
Allergen, Adjuvant Trial type Patient numbers Ref
ILIT Bee venom, extract, alum Open label 8 Senti and Kündig in preparation
Bee venom, extract, alum Multicenter RcT 67 Senti and Kündig in preparation
Grass pollen, extract, alum DB RcT 20 Senti et al.135
Recombinant Fel d1, alum DB RcT 58 Senti et al.139
Grass pollen, extract, alum DB RcT 45 Malling et al.136
EPIT Grass pollen, patch DB RcT 37 Senti et al.54
Grass pollen, patch DB RcT 30 (children) agostinis et al.69
Grass pollen, patch DB RcT 132 Senti et al.68
Grass pollen, patch DB RcT 98 Senti and Kündig in preparation
cow milk allergy, Viaskin® patch DB RcT 19 (children) Dupont et al.45
peanut allergy, Viaskin® patch DB RcT 110 NcT01170286
abbreviations: RcT, randomized controlled trial; DB RcT, double blinded randomized controlled trial; alum, aluminum hydroxide.
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The first study was followed up with another phase I/IIa trial 
with 132 patients in order to define optimal allergen doses.68 
Hay-fever symptoms during the pollen season were reduced by 
more than 30% in the first year and by 24% in the second year 
in the high-dose group when compared with those in the pla-
cebo group. The alleviation of symptoms in the follow-up year 
was dependent on the treatment dose, but higher allergen doses 
were associated with more local adverse events (AEs), manifested 
by pruritus, erythema, wheal or eczema. Eleven (8.3%) systemic 
AEs of grades 1 to 2 required treatment and led to study exclu-
sion. No drug-related serious AE was recorded.
A third placebo-controlled trial, including 98 patients, was 
initiated in 2009 and recently completed (NCT00777374). The 
goal of this study was to further compare the efficacy of EPIT 
using the combined symptom medication score as well measur-
ing immunological responses. Results are expected in 2013. In 
support of our results, Agostinis and coworkers recently demon-
strated efficacy and safety of EPIT when used as a treatment for 
grass pollen allergy in children.69 Hay fever symptoms as well as 
antihistamine use were significantly reduced in the active treat-
ment group.
Furthermore, the French company DBV Technologies cur-
rently develops an occlusive patch for EPIT. It is known that the 
atopy patch test can induce an eczematous skin reaction even 
on intact skin.70 This suggests efficient antigen penetration, and 
DBV Technologies has confirmed this with an occlusive patch 
initially developed for diagnostic purposes (Diallertest).45,46,71 
Known commercially as Viaskin®, this epidermal delivery system 
(EDS) relies on the ability to deliver whole protein molecules to 
the skin, facilitated through hydration of the stratum corneum 
under an occlusive chamber. Whole protein, delivered via such 
a system, has been demonstrated to accumulate in the stratum 
corneum, from where it diffuses down to immune cells in the 
viable layers of the epidermis.46,71,72 Murine studies, designed 
to test therapeutic efficacy of the Viaskin® EDS, demonstrated 
equivalence of EPIT and SCIT46 as well as EPIT and SLIT73 in 
preventing allergic airway reactions upon airway allergen chal-
lenge. Moreover, EPIT using the Viaskin® EDS was also efficient 
in the treatment of food allergy as measured by prevention of 
mast cell degranulation upon oral allergen challenge.71,74 A clini-
cal pilot trial was launched to test efficacy and safety of Viaskin® 
EDS EPIT in children with allergy to cow milk. The treatment 
was well tolerated with no serious systemic allergic reaction, but 
there was a significant increase in local eczematous reactions.45 A 
trend toward greater tolerance to cow milk was observed in the 
treated group upon food provocation. Phase I (NCT01170286) 
and phase II trials (NCT01197053) have been initiated to sub-
stantiate these findings when using Viaskin® EDS for treatment 
against peanut allergy.
Intralymphatic Immunotherapy
Immunological specialties of the lymph nodes. T- and B-cell 
receptors are randomly rearranged to generate a large repertoire 
of lymphocytes that can specifically recognize all possible anti-
gens. Conversely, however, the frequencies of antigen-specific 
penetration of antigens through the epidermis can be enhanced 
by skin hydration over a time period of at least 4 to 10 h.44 This 
is typically achieved by application of an occlusive patch leading 
to sweat accumulation.45,46
Allergen-specific immunotherapy by topical epicutane-
ous administration. Despite the ancient success of epicutane-
ous smallpox vaccination,47 this route of administration did not 
attract major attention until the end of the 20th century, when 
Glenn and coworkers demonstrated efficacious transcutaneous 
vaccination against numerous infectious diseases as well as can-
cer.33,34,48-53 A decade later, our group published the first placebo 
controlled trial on allergen-specific epicutaneous immunother-
apy (EPIT).54
However, the first records describing the administration of 
allergens via the skin date back to 1929. Soon after the intro-
duction of SCIT by Leonard Noon,6 the risk of suffering from 
anaphylaxis and other allergic adverse events upon subcutaneous 
allergen administration was recognized as a real problem55 and 
spurred testing of intradermal pollen extract administrations.56 
Similar to the intradermal allergy testing of today, pollen extracts 
were applied to the skin. The authors reported that the treatment 
was safe and highly successful with symptom amelioration in all 
the 29 patients after administration of three doses.
Another event that suggested the potential suitability of 
EPIT was an observation reported in 1921, when an asthmatic 
patient experienced complete symptom relief after administra-
tion of horse dander on scarificated skin, a method called “cuti-
réactions répétées.”57 Then, French allergologists paved the way 
for EPIT during the 1950s and 60s. Pautrizel and coworkers58 
administered allergen extracts onto epidermis that was slightly 
rubbed, while the team of Blamoutier59,60 applied allergen drops 
onto heavily scarified skin, a method called “méthode de qua-
drillage cutané.” Both groups observed high treatment success, 
but while the former method required a large number of applica-
tions the method of Blamoutier could be performed co-season-
ally with significant symptom amelioration after an average of 
four treatments. Both methods were associated with fewer and 
milder allergic side effects than typically observed with SCIT.58-60 
Several confirmatory trials were performed in the following years 
by the Swiss clinicians Eichenberger and Storck, who reported a 
treatment success rate of approximately 80%.61 Symptoms rap-
idly diminished after a single application, and the effect lasted 
from three days to three weeks. Hence, 6 to 12 treatments were 
required for a symptom free season and the method was reported 
to be also effective in patients who responded inadequately to 
conventional SCIT.61-63
Inspired by these early reports, we performed the first ran-
domized placebo-controlled study that tested the clinical efficacy 
and safety of EPIT in patients allergic to grass pollen.54 Twelve 
patches with allergen or placebo were applied on the upper arm, 
before and during the pollen season, and the application area 
was prepared by tape stripping.64-67 A 70% improvement of hay 
fever symptoms in the treated patients was observed, while the 
placebo effect accounted for 20%. No severe systemic allergic 
reactions were observed, but local eczematous skin reactions were 
frequently reported.
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By intralymphatic immunotherapy, only nanograms of proteins 
were required to elicit sufficiently strong immune responses.104 
Likewise, targeted lymph node administration is also extensively 
documented to be the most efficient way to immunize macaques 
against SIV.105 Similar results were obtained in macaques vacci-
nated with other proteins.106-111
Several clinical trials with intranodal therapy have confirmed 
these initial pre-clinical studies. Most of these studies have been 
performed in cancer patients usually as autologous vaccination 
using antigen-pulsed DCs.88,112-118 This treatment was typically 
safe and stimulated antigen-specific and cytotoxic CD8 T-cell 
responses in the patients. Although intralymphatic immuno-
therapy with DCs has been associated with improved survival,112 
increased immune responses were not always followed by marked 
clinical benefits.115 In other cancer trials, the intranodal vaccines 
were based on plasmid DNA119 or plasmid DNA and peptide 
in a prime-boost regime.120,121 Finally, intranodal injections of 
vaccines based on viral vectors have been studied in melanoma 
patients, who responded with strong cytotoxic and other immu-
nological T-cell responses as well as some clinical benefits.122,123
Allergen-specific intralymphatic immunotherapy (ILIT). As 
mentioned above, IgE-mediated allergies, such as allergic rhino-
conjunctivitis and asthma, have become highly prevalent124-127 
and the gold standard of therapy is subcutaneous allergen-specific 
immunotherapy (SCIT), which confers long-term benefits, and 
which interrupts with the atopic march that is the expansion of 
allergic sensitizations to other allergens128 and the progression 
from allergic rhinitis to asthma.129 From a medical perspective, 
SCIT is therefore superior to symptomatic treatments, but its 
efficacy should be improved and the treatment time reduced to 
make SIT more patient friendly.
Therefore, we have investigated whether SCIT could be 
enhanced by intralymphatic administration of allergens. In mice, 
we have demonstrated that ILIT with a variety of allergens, e.g., 
bee venom phospholipase-A2, ovalbumin and allergen extracts 
from grass pollen, birch pollen and cat dander, stimulated anti-
allergic and protective B- and T-cell immune responses.130-134 In 
fact, changing from the subcutaneous route to direct intralym-
phatic injection significantly enhanced the efficacy of immuni-
zation, inducing allergen-specific IgG2a antibody responses that 
were 10–20 times higher with only 0.1% of the allergen dose. 
Since allergic side effects are proportional to the allergen dose, 
intralymphatic SIT should also have the potential to reduce side 
effects, as lower doses of allergens are required for efficacious SIT. 
Moreover, allergen ILIT enhanced IL-1, IFN-γ, IL-4 and IL-10 
secretion when compared with subcutaneous SIT, suggesting 
that ILIT did not polarize the immune response allergen toward 
Th1, Th2 or Tregs, but generated overall stronger responses.
Studies of biodistribution in mice showed that approximately 
100-fold higher allergen doses reached the lymph nodes after 
intralymphatic than after subcutaneous injection in the same 
draining region.132 Similar results were obtained in humans 
when intralymphatic injections were compared with subcuta-
neous injection using radio tracing.81,83 Essentially, when the 
same dose of a 99mTc labeled protein was injected into either a 
superficial inguinal lymph node or subcutaneously at a site just 
lymphocytes are so low (approximately one in ten million) that 
antigens must be presented to millions of T and B cells in order 
to find their match and to elicit a response. Therefore, anti-
gens need to either drain into secondary lymphatic organs or be 
transported there. Here, antigens can be presented to high num-
bers of T and B cells for stimulation of an immune response.75 
Antigens staying outside of secondary lymphoid organs have little 
chance to encounter specific T or B cells and are therefore poorly 
immunogenic.76-78
Lymph vessels drain substances from the interstitial fluid into 
regional lymph nodes with highly variable efficiency. As lymph 
vessels have evolved to drain pathogens into lymph nodes, viruses 
and small particles (20–200 nm) drain freely and efficiently 
from the peripheral sites into lymph nodes. However, only a low 
percentage of the particles drain into the lymph nodes.79 Larger 
bacteria and particles (500–2000 nm) are mostly transported 
into lymph nodes by DCs and other APCs. On the other hand, 
drainage of non-particulate antigens from the periphery to lymph 
nodes is typically less efficient and only one thousandth to one 
millionth of the antigen dose reaches the lymph nodes. Because 
many of the currently used vaccines are non-particulate, one may 
expect that the direct administration of a vaccine into a lymph 
node would increase antigen presentation and stimulation of 
immune responses.
Intralymphatic immunotherapy. A large number of studies, 
both pre-clinical and clinical have been based on the intralym-
phatic administration of drug or vaccines. In humans, the drug 
or vaccine preparations are typically administered intralymphati-
cally into an inguinal lymph node under ultrasound control, a 
procedure that is uncomplicated and performed routinely by 
sonologists as well as by radiologists for the administration of 
imaging agents. For a comprehensive review, see references 12 
and 80–83.
Antigen pulsed DCs injected into the lymph node localize 
to the paracortex.84-86 As DCs and T cells are present at very 
high densities in lymph nodes, co-stimulatory signals for T- and 
B-cell induction may be provided as a bystander effect. While 
some clinical trials using intranodal therapy with DCs have 
suggested enhanced immune responses,87,88 other trials failed 
to demonstrate advantage of intranodal over intradermal DCs 
delivery.84,89 We also found that non-professional APCs, such as a 
fibro-sarcoma cell line efficiently induced antigen specific CD8+ 
T-cell responses in lymph nodes via direct antigen presentation 
on the MHC class I molecule present on the fibro-sarcoma.76,90 
Intranodal therapy with tumor cells has been tried in both 
human cancer patients and dogs with indication of success.91-95
Direct administration of MHC class I binding peptide vac-
cines into lymph nodes or the spleen has been demonstrated to 
enhance CD8 T-cell responses that were protective against viral 
challenge and tumor growth in mice.96 Similarly, intranodal 
immunisation also dramatically enhanced the efficacy of plasmid 
DNA vaccination in mice97-99 as well as RNA vaccination.100-102
Intranodal immunisation with proteins for induction of 
antibodies was performed surprisingly early. At a time when 
it was difficult to purify high quantities of proteins, research-
ers were looking for a more efficient route of immunisation.103 
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intralymphatic allergen administration enhanced safety and effi-
cacy of immunotherapy and could reduce treatment time from 
three years to eight weeks.
In a recently reported Danish clinical trial on ILIT in grass 
pollen allergic patients by Malling and coworkers, three and six 
low dose intralymphatic injections were found to induce IgG4, 
but in contrast to the described Swiss trial, no reduction in hay 
fever symptoms could be found.136 Hay fever symptoms actually 
worsened when compared with placebo, and IgE was boosted 
after allergen ILIT. In the Danish trial, intralymphatic grass pol-
len extract injections were given on a weekly interval, and not 
monthly, as in the Swiss trial.135 Experience from vaccine immu-
nology recommends a time interval between priming injections 
of at least three weeks to allow development of successive waves 
of antigen specific primary responses and affinity maturation of 
memory B cells.137 Also, the continued antigen presentation gen-
erated by weekly administration in the Danish trial by Malling 
and coworkers may have favored boosting of Th2 responses, as 
has been previously demonstrated in mouse models.138 With the 
on-and-off allergen profile generated by monthly injections in the 
Swiss trial, no boosting of IgE was observed.135
Recently, we applied ILIT using a MHC class II-targeting 
cat dander allergen; a recombinant Fel d 1 conjugated to a TAT 
translocation sequence and invariant chain (MAT-Fel d 1). In 
this randomized, placebo-controlled and double-blind trial, ILIT 
with MAT-Fel d 1 in alum was compared with ILIT with placebo 
in cat dander allergic patients.139 Three monthly injections with 
MAT-Fel d 1 elicited no adverse events, and there was significant 
increase in allergen tolerance after nasal provocation. In addi-
tion, allergen ILIT stimulated regulatory T-cell responses with 
IL-10 cytokine secretion and increased cat dander-specific IgG4 
production.
Conclusions
The ideal route for allergen-specific immunotherapy is one with 
a high density of potent professional APCs, so that immuno-
genicity of the allergen is increased enabling dose-reduction as 
well as reduction of the number of allergen administrations. 
Also the ideal route of allergen immunotherapy should con-
tain only few mast cells to avoid local allergic reactions, and 
vascularization should be poor to minimize the risk of aller-
gen leakage or inadvertent intravascular allergen administration 
entailing severe anaphylactic side effects. Both, the epidermis 
and the lymph node contain a high density of DCs. While 
lymph nodes contain very few mast cells, the epidermis contains 
none. Further advantages of the epidermis as route of allergen 
administration are the accessibility and fact that the epithelium 
is not vascularized.
It has been verified in clinical trials that both safety and effi-
cacy of intranodal SIT (ILIT) is improved when compared with 
conventional subcutaneous SIT (SCIT). For epicutaneous SIT 
(EPIT), clinical comparisons with SCIT have not yet been done 
because current guidelines for testing efficacy of SIT require pla-
cebo control instead of SCIT control. The type of allergens suit-
able for ILIT and EPIT are in principle the same as those suitable 
10 cm above the contralateral inguinal lymph node, only a small 
fraction of the subcutaneously administered protein reached the 
lymph nodes after 4 h and this fraction did not increase after 
24 h. However, within 20 min of the intralymphatic injection, 
the protein drained into the deep subcutaneous lymph nodes and 
even further into a pelvic lymph node. These experiments clearly 
demonstrated the potential of allergen ILIT to that of allergen 
SCIT.
Clinical trials with allergen ILIT. In a first clinical trial, 
eight patients with bee-venom allergy grade III, who would 
have received approximately 70 subcutaneous injections of 
each 100 μg bee venom extract under normal SCIT protocol, 
received three injections of only 10 μg directly into the ingui-
nal lymph node. In this proof of concept trial, seven out of the 
eight treated patients were protected against a subsequent bee 
sting challenge. In a larger multicenter clinical trial conducted 
after the pilot study with 66 grade III and IV bee venom aller-
gic patients, allergen-ILIT-mediated protection was shown to 
correlate with immunological parameters (Senti et al., manu-
script in preparation). The safety and efficacy of intranodal bee 
venom allergen extract (Bee AlleVax) was further tested in a 
multicenter study. Between 2001 and 2003, 67 subjects from 
15 centers across Europe and in Australia were randomized to 
receive either 10 or 20 μg doses of Bee AlleVaxTM via intrano-
dal injections. Clinical endpoints included bee venom specific 
IgE and IgG serum levels and the degree of protection after a 
bee sting challenge. Desensitization by ILIT not only resulted 
in increased IgG and IgE levels, but also in a high number of 
serious adverse events occurring both after ILIT and after bee 
sting challenge. For this reason, the study was terminated by the 
sponsors. The high number of serious adverse events may sug-
gest that the immunological protection offered by Bee AlleVaxTM 
was insufficient. Two confounding factors may explain the fail-
ure of Bee AlleVaxTM. First, a major fraction of the bee venom 
extract remained un-absorbed to the alum (personal communi-
cation from S.J. McCormack, former CEO of AlleCure Corp.). 
This may cause vascular leakage of free allergen. Second, the 
bee venom allergen extract was prepared in US using American 
honey bees and the studies were done on patients from Europe 
and Australia, and it is known that continental differences in the 
content of bee venom allergens exists.
In another Swiss trial, 165 patients with grass pollen-induced 
rhino-conjunctivitis were randomized to receive either 54 subcu-
taneous injections with pollen extract over three years [cumula-
tive allergen dose 4,031,540 standardized quality units (SQ-U)] 
or three intralymphatic injections over two months (cumula-
tive allergen dose 3,000 SQ-U); the trial was monocentric and 
open labeled.135 Patients were evaluated after four months, one 
year and three years. Three low-dose intralymphatic allergen 
administrations increased tolerance upon nasal provocation with 
pollen within four months after treatment. Tolerance was long 
lasting and equivalent to that achieved after standard SCIT. 
Allergen ILIT ameliorated hay fever symptoms, reduced skin 
prick test reactivity, decreased specific IgE in serum and caused 
fewer adverse events than did SCIT. ILIT also enhanced compli-
ance and was less painful than venous puncture. In conclusion, 
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for SCIT. However, from a safety viewpoint, SIT with allergens 
that have very high affinity to IgE would surely benefit from ILIT 
as ILIT enables effective therapy with much lower doses than 
those required in effective SCIT. In conclusion, both the lymph 
node and the epidermis represent highly interesting routes for 
allergen immunotherapy, combining the advantages of high den-
sity of APCs and low frequency of mast cells and few vascular 
structures, factors that enable dose reduction, reduction of doctor 
visits and side effects.
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